Impact of Genetic Mutations and Health Plan Access to Therapies on Treatment Response and Drug Costs Related to Tyrosine Kinase Inhibitor Treatment among Patients with Chronic Myelogenous Leukemia

Elias Jabbour, Dinara Makenbaeva, Melissa Lingohr-Smith, Jay Lin

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Fingerprint

Dive into the research topics of 'Impact of Genetic Mutations and Health Plan Access to Therapies on Treatment Response and Drug Costs Related to Tyrosine Kinase Inhibitor Treatment among Patients with Chronic Myelogenous Leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences